Research programme: genome editing therapeutics - Editas Medicine

Drug Profile

Research programme: genome editing therapeutics - Editas Medicine

Alternative Names: LCA10 program

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Editas Medicine
  • Class Gene therapies
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alpha 1-antitrypsin deficiency; Cystic fibrosis; Duchenne muscular dystrophy; Eye disorders; Haematological disorders; Leber congenital amaurosis

Most Recent Events

  • 14 Mar 2017 Editas Medicines and Allergan enter an options agreement for genome editing therapeutics
  • 14 Mar 2017 Editas Medicine in-licenses specified patent rights, related to certain Cas9 compositions of matter and their use for gene editing from Broad Institute, Harvard College, Massachusetts Institute of Technology, Rockefeller University, Howard Hughes Medical Institute (Editas Medicine Form 10-K, March 2017)
  • 14 Mar 2017 Editas Medicine has patents pending for CRISPR technology and composition of matter and method of use claims for therapeutic programs, including LCA 10 and other genetic and infectious eye disorders, and engineered T-cells in Europe, USA and jurisdictions outside USA and Europe (Form 10-K, March 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top